Seeking Alpha

Celgene's (CELG -0.1%) Apremilast drug significantly improved the signs and symptoms of patients...

Celgene's (CELG -0.1%) Apremilast drug significantly improved the signs and symptoms of patients with psoriatic arthritis in the company's "Palace 3" Phase III study. The results come a day after Celgene reported a positive outcome from "Palace I". In total, the company is conducting four Phase III "Palace" trials. (PR)
Comments (1)
  • heffera
    , contributor
    Comments (6) | Send Message
     
    somewhat expected, but should have a beneficial effect on FDA approval. As a non-biologic, it has other treatment merits as well.
    13 Jun 2013, 02:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs